Replies to post #144339 on Biotech Values

[DewDiligence]

Is it often that the one appealing will win in a patent case like this?

Please clarify what you mean by the phrase like this? Reversals of US drug-patent cases on appeal are more common than some investors think; for instance, it happened with Norvasc (which at the time was PFE’s second-largest drug)—see #msg-18124296.